Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 20 de 20 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Jayadevappa R, Chhatre S, Malcowikz B, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Network Open 2019;2:e196562. [Ref.ID 103156]
2. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
3. Cita con resumen
Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncology 2016:13 de octubre. [Ref.ID 100814]
4. Cita con resumen
Anónimo. Enzalutamide. Prescrire 2014;34:330-4. [Ref.ID 97555]
6.
Anónimo. Degarelix (Firmagon) for prostate cancer. Med Lett Drugs Ther 2009;51:82-3. [Ref.ID 87348]
7.
Anónimo. Les pneumopathies interstitielles dues à des médicaments. Prescrire 2007;27:510-2. [Ref.ID 80442]
8.Tiene citas relacionadas
Ahmad SR, Graham DJ. Pneumonitis with antiandrogens. In response. Ann Intern Med 2003;139:529. [Ref.ID 67435]
9.Tiene citas relacionadas
Ahmad SR, Graham DJ. Pneumonitis with antiandrogens. Ann Intern Med 2003;139:528-9. [Ref.ID 67434]
11. Cita con resumen
Ahmad SR, Graham DJ, Toyer DP, Wassel R, Mann M. Comparison of pulmonary toxicity risks with antiandrogens. Pharmacoepidemiol Drug Saf 2000;9:S121. [Ref.ID 53238]
12.Tiene citas relacionadas
Dalesio O, van Tinteren H, Peto R, Clarke M, Schröder FH. Androgen blockade in prostate cancer. Authors' reply. Lancet 2000;356:341-2. [Ref.ID 52182]
13.Tiene citas relacionadas
Labrie F, Candas B. Androgen blockade in prostate cancer. Lancet 2000;356:341. [Ref.ID 52181]
14.Tiene citas relacionadas Cita con resumen
Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000;355:1491-8. [Ref.ID 50637]
15.Tiene citas relacionadas Cita con resumen
Reese D M. Choice of hormonal therapy for prostate cancer. Lancet 2000;355:1474-5. [Ref.ID 50632]
16.Tiene citas relacionadas
Eisenberger M, Blumenstein BA. Hormonal treatment of prostate cancer. The authors reply. N Engl J Med 1999;340:812-3. [Ref.ID 43210]
17.
Mahler Ch, Verhelst J, Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin Pharmacokinet 1998;34:405-17. [Ref.ID 39252]
18.
Rane A. Endocrine and adrenergic pharmacological intervention in diseases of the prostate. Br J Clin Pharmacol 1998;45:329-37. [Ref.ID 38385]
19.
Dole EJ, Holdsworth MT. Nilutamide for prostate cancer. Ann Pharmacother 1997;31:65-75. [Ref.ID 31871]
20.
Jonville AP, Diot E, Dutertre JP, Autret E. Toxicité pulmonaire du nilutamide (Anandron®). Therapie 1992;47:393-7. [Ref.ID 18505]
Seleccionar todas
 
 1 a 20 de 20